Spanish Red Biotech Pipeline

Sylentis

Tivanisirán (SYL1001)

Type: Biodrugs/ Drugs
Therapeutic area:
Indication: Dry eye disease
Phase: 3Phase III, 2Phase II, 1Phase I, 2Regulatory Preclinical, 1Non Regulatory Preclinical